[The immunomodulating action of cyclosporin A in vitro and in vivo on the lymphocytes of patients with alveolitis].
The paper presents the first results of using cyclosporin A (CsA) to treat lymphocytes during their extracorporeal immunomodulation (EIL) in patient with fibrotic alveolitis of various etiology. Two-hour lymphocytic incubation in the medium containing 0.1-10 micrograms per ml of CsA was sufficient for CsA to show its in vitro immunosuppressive effect, which resulted in a substantial inhibition of a proliferative lymphocytic response to mitogens and antigens. Administration of CsA-treated lymphocytes induced no profound structural changes in lymphocytic subpopulations (CD3, CD4, CD8), but it was followed by a reduction in the baseline high proliferative lymphocytic response to PHA. The clinical effect, alveolitis alleviation was noted in all patients. It is suggested that clinical effects may be produced by a local concentration of the treated lymphocytes and their transferred CsA as well.
Kosmiadi
G A
GA
Abramova
Z P
ZP
Vaneeva
T V
TV
Fomina
N M
NM
Gergert
V Ia
VIa
Shmelev
E I
EI
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D001804:Blood Transfusion, Autologous / Q000379:methods; D002455:Cell Division / Q000187:drug effects; D002469:Cell Separation; D002478:Cells, Cultured; D016572:Cyclosporine / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D016131:Lymphocyte Subsets / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D017710:Lymphocyte Transfusion / Q000379:methods*; D011658:Pulmonary Fibrosis / Q000276:immunology* / Q000628:therapy
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D016572:Cyclosporine